NeuroMetrix, Inc. (NURO)

Market Cap	9.22M
Revenue (ttm)	4.38M
Net Income (ttm)	-7.94M
Shares Out	2.03M
EPS (ttm)	-5.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,676
Open	4.580
Previous Close	4.580
Day's Range	4.350 - 4.600
52-Week Range	2.660 - 5.600
Beta	2.29
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About NURO

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disp...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1996
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: NURO
• Website: https://www.neurometrix.com

Financial Performance

In 2023, NeuroMetrix's revenue was $5.90 million, a decrease of -28.52% compared to the previous year's $8.26 million. Losses were -$6.53 million, 47.8% more than in 2022.